{"entity":"abbott-laboratories","id":"ent_abbott-laboratories","name":"Abbott Laboratories","from":"2025-11-09","to":"2026-11-09","page":"https://asof.is/record/abbott-laboratories/diff?from=2025-11-09&to=2026-11-09","summary":"Between 2025-11-09 and 2026-11-09, Abbott Laboratories's record changed in 20 facts: 4 replaced (net income $13.4 billion → $6.52 billion; operating income $6.83 billion → $8.05 billion; research and development $2.84 billion → $2.94 billion and 1 more), 8 added, 8 ended; 12 unchanged.","counts":{"changed":20,"added":8,"ended":8,"replaced":4,"unchanged":12,"skipped_posts":{"from":0,"to":0}},"by_predicate":[{"predicate":"cash_and_equivalents","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"quarterly_net_income","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"quarterly_operating_income","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"quarterly_research_and_development","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"quarterly_revenue","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"shares_outstanding","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"total_assets","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"total_equity","added":1,"ended":1,"replaced":0,"unchanged":0},{"predicate":"net_income","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"operating_income","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"research_and_development","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"revenue","added":0,"ended":0,"replaced":1,"unchanged":0},{"predicate":"cfo","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"cik","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"fiscal_year_end","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"headquarters","added":0,"ended":0,"replaced":0,"unchanged":2},{"predicate":"listed_on","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"registrant_name","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"sic_industry","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"state_of_incorporation","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"ticker","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"website","added":0,"ended":0,"replaced":0,"unchanged":1},{"predicate":"x_username","added":0,"ended":0,"replaced":0,"unchanged":1}],"added":[{"id":"clm_D623F1D8651F","predicate":"cash_and_equivalents","value":"4,052,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 4,052,000,000 United States dollar\", as of 2026-09-30. Claim clm_D623F1D8651F, https://asof.is/claim/clm_D623F1D8651F, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_D623F1D8651F","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2026, filed 2026-11-04"}},{"id":"clm_0E055280C61A","predicate":"quarterly_net_income","value":"920,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 920,000,000 United States dollar\", as of 2026-09-30. Claim clm_0E055280C61A, https://asof.is/claim/clm_0E055280C61A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_0E055280C61A","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2026, filed 2026-11-04"}},{"id":"clm_2416CD508AED","predicate":"quarterly_operating_income","value":"1,358,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,358,000,000 United States dollar\", as of 2026-09-30. Claim clm_2416CD508AED, https://asof.is/claim/clm_2416CD508AED, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_2416CD508AED","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2026, filed 2026-11-04"}},{"id":"clm_1E22065402A1","predicate":"quarterly_research_and_development","value":"920,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 920,000,000 United States dollar\", as of 2026-09-30. Claim clm_1E22065402A1, https://asof.is/claim/clm_1E22065402A1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_1E22065402A1","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2026, filed 2026-11-04"}},{"id":"clm_080974839279","predicate":"quarterly_revenue","value":"13,013,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 13,013,000,000 United States dollar\", as of 2026-09-30. Claim clm_080974839279, https://asof.is/claim/clm_080974839279, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_080974839279","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2026, filed 2026-11-04"}},{"id":"clm_7B940234185D","predicate":"shares_outstanding","value":"1,731,941,601 shares","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,731,941,601 shares\", as of 2026-09-30. Claim clm_7B940234185D, https://asof.is/claim/clm_7B940234185D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_7B940234185D","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2026, filed 2026-11-04"}},{"id":"clm_408FF4DCACA7","predicate":"total_assets","value":"108,247,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 108,247,000,000 United States dollar\", as of 2026-09-30. Claim clm_408FF4DCACA7, https://asof.is/claim/clm_408FF4DCACA7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_408FF4DCACA7","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2026, filed 2026-11-04"}},{"id":"clm_1774BA675DC1","predicate":"total_equity","value":"51,027,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 51,027,000,000 United States dollar\", as of 2026-09-30. Claim clm_1774BA675DC1, https://asof.is/claim/clm_1774BA675DC1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_1774BA675DC1","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2026, filed 2026-11-04"}}],"ended":[{"id":"clm_4D88D9F7190C","predicate":"cash_and_equivalents","value":"7,511,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 7,511,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_4D88D9F7190C, https://asof.is/claim/clm_4D88D9F7190C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_4D88D9F7190C","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_C0C2E64C6F88","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-29T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2025, filed 2025-10-29"}},{"id":"clm_2BCC0DA601EA","predicate":"quarterly_net_income","value":"1,644,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 1,644,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_2BCC0DA601EA, https://asof.is/claim/clm_2BCC0DA601EA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_2BCC0DA601EA","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0713CDEDD078","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-29T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-10-29"}},{"id":"clm_94C2592AE159","predicate":"quarterly_operating_income","value":"2,057,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 2,057,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_94C2592AE159, https://asof.is/claim/clm_94C2592AE159, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_94C2592AE159","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_1C0A2724D779","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-29T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2025, filed 2025-10-29"}},{"id":"clm_1266BBB313EF","predicate":"quarterly_research_and_development","value":"766,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 766,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_1266BBB313EF, https://asof.is/claim/clm_1266BBB313EF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_1266BBB313EF","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_F408F42211E9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-29T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2025, filed 2025-10-29"}},{"id":"clm_4D4D4E6FC869","predicate":"quarterly_revenue","value":"11,369,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2026-03-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 11,369,000,000 United States dollar\", as of 2025-09-30 (until 2026-03-31). Claim clm_4D4D4E6FC869, https://asof.is/claim/clm_4D4D4E6FC869, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_4D4D4E6FC869","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_EF0BC6C103EE","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-29T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2025, filed 2025-10-29"}},{"id":"clm_0F8EC0C78816","predicate":"shares_outstanding","value":"1,738,871,947 shares","valid_from":"2025-09-30","valid_to":"2026-01-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,738,871,947 shares\", as of 2025-09-30 (until 2026-01-31). Claim clm_0F8EC0C78816, https://asof.is/claim/clm_0F8EC0C78816, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_0F8EC0C78816","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_98DC25486509","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-29T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-10-29"}},{"id":"clm_87D9C9A99CA7","predicate":"total_assets","value":"84,181,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 84,181,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_87D9C9A99CA7, https://asof.is/claim/clm_87D9C9A99CA7, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_87D9C9A99CA7","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_61EE170DDFF9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-29T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-10-29"}},{"id":"clm_D5EE83B1870A","predicate":"total_equity","value":"50,954,000,000 United States dollar","valid_from":"2025-09-30","valid_to":"2025-12-31","published":"2025-10-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 50,954,000,000 United States dollar\", as of 2025-09-30 (until 2025-12-31). Claim clm_D5EE83B1870A, https://asof.is/claim/clm_D5EE83B1870A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm.","url":"https://asof.is/claim/clm_D5EE83B1870A","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_233C6F73AC72","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025047131/0001628280-25-047131-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2025","published_at":"2025-10-29T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-10-29"}}],"replaced":[{"predicate":"net_income","from":{"id":"clm_CF3E98D0B268","predicate":"net_income","value":"13,402,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories net income: 13,402,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_CF3E98D0B268, https://asof.is/claim/clm_CF3E98D0B268, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm.","url":"https://asof.is/claim/clm_CF3E98D0B268","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_76AC317902A6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-21T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-21"}},"to":{"id":"clm_76AC317902A6","predicate":"net_income","value":"6,524,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories net income: 6,524,000,000 United States dollar\", as of 2025-12-31. Claim clm_76AC317902A6, https://asof.is/claim/clm_76AC317902A6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm.","url":"https://asof.is/claim/clm_76AC317902A6","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-20T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2025, filed 2026-02-20"}}},{"predicate":"operating_income","from":{"id":"clm_6578DDE458E0","predicate":"operating_income","value":"6,825,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories operating income: 6,825,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_6578DDE458E0, https://asof.is/claim/clm_6578DDE458E0, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm.","url":"https://asof.is/claim/clm_6578DDE458E0","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_551396362E4C","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-21T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2024, filed 2025-02-21"}},"to":{"id":"clm_551396362E4C","predicate":"operating_income","value":"8,053,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories operating income: 8,053,000,000 United States dollar\", as of 2025-12-31. Claim clm_551396362E4C, https://asof.is/claim/clm_551396362E4C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm.","url":"https://asof.is/claim/clm_551396362E4C","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-20T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2025, filed 2026-02-20"}}},{"predicate":"research_and_development","from":{"id":"clm_AD76C5C835C9","predicate":"research_and_development","value":"2,844,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories research and development: 2,844,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_AD76C5C835C9, https://asof.is/claim/clm_AD76C5C835C9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm.","url":"https://asof.is/claim/clm_AD76C5C835C9","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_0537D98543E9","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-21T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2024, filed 2025-02-21"}},"to":{"id":"clm_0537D98543E9","predicate":"research_and_development","value":"2,942,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories research and development: 2,942,000,000 United States dollar\", as of 2025-12-31. Claim clm_0537D98543E9, https://asof.is/claim/clm_0537D98543E9, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm.","url":"https://asof.is/claim/clm_0537D98543E9","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-20T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2025, filed 2026-02-20"}}},{"predicate":"revenue","from":{"id":"clm_AC0EC8434FB1","predicate":"revenue","value":"41,950,000,000 United States dollar","valid_from":"2024-12-31","valid_to":"2025-12-31","published":"2025-02-21","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories revenue: 41,950,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_AC0EC8434FB1, https://asof.is/claim/clm_AC0EC8434FB1, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm.","url":"https://asof.is/claim/clm_AC0EC8434FB1","accessed":"2026-11-09"},"confidence":0.95,"status":"superseded","assertable":true,"superseded_by":"clm_7C1D7352CFA6","sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828025007110/0001628280-25-007110-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2024","published_at":"2025-02-21T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2024, filed 2025-02-21"}},"to":{"id":"clm_7C1D7352CFA6","predicate":"revenue","value":"44,328,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories revenue: 44,328,000,000 United States dollar\", as of 2025-12-31. Claim clm_7C1D7352CFA6, https://asof.is/claim/clm_7C1D7352CFA6, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm.","url":"https://asof.is/claim/clm_7C1D7352CFA6","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-20T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2025, filed 2026-02-20"}}}],"rule":"Two states compared by claim id: in both, unchanged; only on to, added; only on from, ended. An ended and an added claim on one predicate are a replacement when the ended one points to the added (superseded_by), or the predicate has exactly one of each and the added begins the day the ended ends. Added rows are labelled for to, ended rows for from. Posts and Hugging Face repos are counted in skipped_posts, not listed.","legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing"}}}